Karyotypic Imbalances and Differential Gene Expressions in the Acquired Doxorubicin Resistance of Hepatocellular Carcinoma Cells
Laboratory Investigation (2005) 85, 664–674 & 2005 USCAP, Inc All rights reserved 0023-6837/05 $30.00 www.laboratoryinvestigation.org Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells Elizabeth Pang1, Ying Hu1, Kathy Y-Y Chan2, Paul B-S Lai3, Jeremy A Squire4, Pascale F Macgregor5, Ben Beheshti4, Monique Albert5, Thomas W-T Leung6 and Nathalie Wong2 1Department of Clinical Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China; 2Department of Anatomical and Cellular Pathology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China; 3Department of Surgery, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Shatin, NT, Hong Kong SAR, China; 4Departments of Medical Biophysics and Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada M5G 2L9; 5Microarray Centre, Clinical Genomics Centre, University Health Network, Toronto, Ontario, Canada M5G 2C4 and 6Oncology Centre, Hong Kong Sanatorium & Hospital, Hong Kong SAR, China Administration of doxorubicin has been shown to prolong survival of patients with hepatocellular carcinoma (HCC). However, treatment regimen is often complicated by the emergence of drug resistance. The goal of our study is to enhance our understanding on the genetic changes that confer cellular chemoresistance to doxorubicin. To model this insensitive response, we established five doxorubicin-resistant (DOR) sublines through repeated exposure of escalating doses of doxorubicin to HCC cell lines (HKCI-2, -3, -4, -C1 and -C2). The DOR sublines developed displayed an average B17-fold higher IC50 value than their sensitive parental cell lines.
[Show full text]